MX2009005855A - Formulaciones inhalables de bisfosfonato enlazado con polimero y metodos de uso de las mismas. - Google Patents

Formulaciones inhalables de bisfosfonato enlazado con polimero y metodos de uso de las mismas.

Info

Publication number
MX2009005855A
MX2009005855A MX2009005855A MX2009005855A MX2009005855A MX 2009005855 A MX2009005855 A MX 2009005855A MX 2009005855 A MX2009005855 A MX 2009005855A MX 2009005855 A MX2009005855 A MX 2009005855A MX 2009005855 A MX2009005855 A MX 2009005855A
Authority
MX
Mexico
Prior art keywords
active agent
methods
bisphosphonate
polymer
bisphosphonate active
Prior art date
Application number
MX2009005855A
Other languages
English (en)
Inventor
Akira Yamamoto
Maria Nakatani
Hidemasa Katsumi
Original Assignee
Teikoku Pharma Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teikoku Pharma Usa Inc filed Critical Teikoku Pharma Usa Inc
Publication of MX2009005855A publication Critical patent/MX2009005855A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/67—Phosphorus compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención provee métodos de administración de un agente activo de bisfosfonato a un sujeto en necesidad del mismo; los aspectos de la invención incluyen administrar el agente activo de bisfosfonato al sujeto mediante una vía pulmonar, en donde el agente activo de bisfosfonato está enlazado, ya sea directamente o por medio de un grupo enlazador intermedio, a un polímero no peptídico, de modo que el agente activo de bisfosfonato es un agente activo de bisfosfonato enlazado a polímero; también se proveen composiciones para usarse en la práctica de los métodos de acuerdo con las modalidades de la invención; los métodos y composiciones de acuerdo con las modalidades de la invención tienen utilidad en una variedad de aplicaciones diferentes, que incluyen sin limitación el tratamiento de condiciones patológicas de adsorción de hueso.
MX2009005855A 2007-01-26 2007-12-27 Formulaciones inhalables de bisfosfonato enlazado con polimero y metodos de uso de las mismas. MX2009005855A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89755307P 2007-01-26 2007-01-26
PCT/US2007/026427 WO2008091337A1 (en) 2007-01-26 2007-12-27 Polymer-linked-bisphosphonate inhalant formulations and methods for using the same

Publications (1)

Publication Number Publication Date
MX2009005855A true MX2009005855A (es) 2009-06-12

Family

ID=39645357

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005855A MX2009005855A (es) 2007-01-26 2007-12-27 Formulaciones inhalables de bisfosfonato enlazado con polimero y metodos de uso de las mismas.

Country Status (15)

Country Link
US (1) US20080182823A1 (es)
EP (1) EP2124964A1 (es)
JP (1) JP2010516762A (es)
KR (1) KR20090104830A (es)
CN (1) CN101588806A (es)
AR (1) AR062344A1 (es)
AU (1) AU2007345280A1 (es)
BR (1) BRPI0719383A2 (es)
CA (1) CA2669406A1 (es)
EA (1) EA200900881A1 (es)
IL (1) IL198520A0 (es)
MX (1) MX2009005855A (es)
TW (1) TW200843782A (es)
WO (1) WO2008091337A1 (es)
ZA (1) ZA200903049B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2926081B1 (fr) * 2008-01-03 2010-02-19 Univ Nantes Derives d'acide hydroxy-bisphosphonique comme vecteur ciblant le tissu osseux
US8834861B2 (en) * 2011-03-10 2014-09-16 International Business Machines Corporation Polycarbonates for delivery of drugs and methods of preparation thereof
GB201200868D0 (en) * 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
CN104086763A (zh) * 2014-04-03 2014-10-08 西南交通大学 用作表面活性剂的含氨基双膦酸盐修饰Brij化合物及其制备方法
CN107011380A (zh) * 2016-01-28 2017-08-04 臧伟 一种二膦酸衍生物及含二膦酸衍生物的组合物治疗骨折的应用
WO2018025809A1 (ja) * 2016-08-01 2018-02-08 株式会社カネカ カルシプロテインパーティクルの吸着材、および吸着除去システムとその利用方法
CN114652845B (zh) * 2022-04-01 2023-10-13 中山莱博瑞辰生物医药有限公司 阿仑膦酸盐偶联聚乙烯醇聚合物、其制备方法及用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
JPH02268190A (ja) * 1989-04-07 1990-11-01 Fujisawa Pharmaceut Co Ltd 医薬化合物とジホスホン酸誘導体の結合体
US6436386B1 (en) * 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
JP2004528365A (ja) * 2001-05-02 2004-09-16 ノバルティス アクチエンゲゼルシャフト 骨再吸収症および骨粗しょう症の処置または予防におけるビスホスホネートの吸入投与方法
US6756354B2 (en) * 2001-09-05 2004-06-29 Deanna Jean Nelson Therapeutic compositions containing oligo (ethylene glycol)-terminated 1,2-dithiolanes and their conjugates
JP2007537297A (ja) * 2004-05-14 2007-12-20 ベイラー カレッジ オブ メディスン 骨質量を調節するための骨を標的化する部分と結合体化したβアドレナリン薬物

Also Published As

Publication number Publication date
BRPI0719383A2 (pt) 2014-02-18
WO2008091337A1 (en) 2008-07-31
ZA200903049B (en) 2010-07-28
IL198520A0 (en) 2010-02-17
JP2010516762A (ja) 2010-05-20
KR20090104830A (ko) 2009-10-06
EA200900881A1 (ru) 2010-02-26
US20080182823A1 (en) 2008-07-31
CA2669406A1 (en) 2008-07-31
CN101588806A (zh) 2009-11-25
TW200843782A (en) 2008-11-16
EP2124964A1 (en) 2009-12-02
AR062344A1 (es) 2008-11-05
AU2007345280A1 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
MX2009005855A (es) Formulaciones inhalables de bisfosfonato enlazado con polimero y metodos de uso de las mismas.
EA201290482A1 (ru) Стабильные составы для лиофилизации терапевтических частиц
MX2012004525A (es) Compuestos.
BR112012016797A2 (pt) intensificador dinâmico de baixo utilizando compressor com equalizador incorporado
EP1784639A4 (en) PROCESS FOR PREPARING FREEZERTED BLOOD PLATES, FLUIDIZED BLOOD PLATES, COMPOSITIONS AND USE METHOD
PH12015501964B1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
WO2011106322A3 (en) Biomarkers for acute ischemic stroke
EP2576578A4 (en) POLYMORPHES OF 2'-O-FUCOSYLLACTOSE AND MANUFACTURE THEREOF
NZ602471A (en) Antagonists of activin-actriia and uses for increasing red blood cell levels
MX2013008883A (es) Composicion de acido hialuronico.
MX348823B (es) Formulaciones estables de linaclotida.
MX2009004467A (es) Compuestos benzoilo amino heterociclilo como activadores de la glucoquinasa (glk).
MX2009004362A (es) Compuestos mediante benzoilo amino heterociclilo util en el tratamiento de una enfermedad a traves de glk.
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
MX2012001660A (es) Formulaciones que contienen linaclotida para adminstracion oral.
TW200731975A (en) Novel combinations of medicaments for the treatment of respiratory diseases
GB0625523D0 (en) In vivo imaging agents
UA98658C2 (uk) Циклічні депсипептиди
MX2012007896A (es) Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica.
WO2008063865A3 (en) Biphosphonate inhalant formulations and methods for using the same
CY1115961T1 (el) Ανυδρη μορφη κρυσταλλικης μηλεϊνικης ορβεπιταντης (orvepitant maleate)
MX2012000954A (es) Composicion far,aceutica topica que incuye la rel-n-[6-[(2r,6s)-2,6-dimetil-4-morfolinil]-3-piridinil]-2-metil- 4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida.
WO2009114325A3 (en) Methotrexate adjuvants to reduce toxicity and methods for using the same
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal